Ann: Two PTX abstracts accepted at prestigious ISCT conference, page-14

by the end of 2023 we should have the following:
• PTX-100 phase 2 trial
• Omnicar in the clinic with the new thermofisher technology and hopefully some interim data
• Initial Cellpryme deal?
• PTX-200 readout

by the end of 2023 we could have the following:
• PTX-100 registrational (fast track approval) trial *very likely*
• Multiple cellpryme deals
• Further Omnicar deals such as partnerships much like our one with MD Anderson
• Joint venture with Thermofisher to develop Omnicar through clinical trials (purely my speculation). If Thermo were looking to acquire prescient, I think they may dip their toes in the water with a JV before committing to a full takeover.


If the Should haves come to fruition, I don’t think a 250M market cap would be unreasonable, that is a share price of approx $0.31

However if the Could haves come to fruition, then you would have to atleast double that I would have thought……. Atleast